Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China

Reuters09-05

Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China

Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology $(CSCO)$ Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable $(MSS)$ colorectal cancer $(CRC)$. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2565656652?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565656652","market":"us","top_or_hot":-1,"title":"Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology <a href=\"https://laohu8.com/S/CSCO\">$(CSCO)$</a> Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a>. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-05 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology <a href=\"https://laohu8.com/S/CSCO\">$(CSCO)$</a> Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a>. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDLbxCv5:1","article_id":"2565656652","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565656652","pubTimestamp":1757080526,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire  on September 05, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","ADAG":"天演药业","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Adagene Inc.在2025年中国CSCO会议上宣布ADG126与帕博利珠单抗联合用药的良好结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ADAG":0.9},"content_text":"Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    \n\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology $(CSCO)$ Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable $(MSS)$ colorectal cancer $(CRC)$. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2565656652","isCrawlerRequest":true}